Prostate cancer is the most common cancer in South African men — and one of the most survivable when found early. Here's the SA picture, your risk factors, how diagnosis and grading work, and every treatment from surveillance to advanced therapy.
No. 1
Most frequently diagnosed cancer in South African men
1 in 6
Approximate lifetime risk for the average SA man
90%+
Five-year survival when prostate cancer is caught early
40–45
Screening start age for Black African men or family history
Prostate cancer occupies a strange position: it's the most frequently diagnosed cancer in South African men, and a leading cause of cancer death — yet when it's found before symptoms appear, five-year survival exceeds 90%, and many cancers found are so slow-growing they never need treatment at all. Almost every death from prostate cancer traces back to one thing: it was found late. And late diagnosis is almost entirely preventable with a blood test.
Roughly 13–15% of all cancers in SA men are prostate cancers — and the pattern of who gets diagnosed late shapes the outcomes.
South African Black men develop prostate cancer at rates among the highest recorded anywhere in the world, and often at younger ages — which is why screening conversations should start at 40–45 rather than 50.
Many men are only diagnosed once symptoms appear, by which point the cancer may have spread beyond the prostate. Late diagnosis is the single biggest reason prostate cancer still kills South African men.
Awareness gaps, cost, distance from care and the discomfort some men feel about prostate exams keep testing rates down across all population groups — the gap screening would close is enormous.
Organisations like CANSA and the Prostate Cancer Foundation of South Africa offer screening drives, support groups and counselling in both sectors, and treatment is available in public hospitals and private oncology centres.
No single cause has been identified, but these factors stack — and they set when your screening should start.
Risk rises sharply with each decade after 50 — most diagnoses occur in men over 65, but higher-risk men should start screening earlier.
One of the highest incidence rates in the world — roughly double the baseline risk, and often more aggressive at diagnosis.
A father or brother with prostate cancer roughly doubles your risk; more than one close relative raises it further, especially if they were diagnosed young.
Inherited mutations better known for breast cancer also significantly raise prostate cancer risk in men — important if these run in your family.
Excess weight is linked to more aggressive disease, and diets high in processed and red meat with few vegetables may add risk.
The most important fact about prostate cancer symptoms is that, early on, there aren't any. Screening does the work your body won't.
Early prostate cancer confined to the gland typically causes no symptoms at all. Men feel completely normal — which is why waiting for symptoms is the most dangerous strategy, and why a simple PSA test does the work your body won't.
These symptoms suggest the cancer has grown beyond the point where it's silent — worth noting that urinary symptoms alone are more often BPH than cancer, but any of the above deserves a same-month appointment.
Each step refines the picture — nothing invasive happens on the strength of one number.
A blood test measuring PSA, plus a digital rectal exam. This is the doorway — a raised or rising PSA doesn't mean cancer, it means it's time to look closer.
A detailed prostate scan that shows suspicious areas with high accuracy — so biopsies are done only when, and precisely where, they're needed.
Small tissue samples taken under local anaesthetic, usually MRI-guided, and examined by a pathologist. This is the only way prostate cancer is confirmed — PSA alone can't do it.
The pathologist grades how aggressive the cells look, from 6 to 10, reported as ISUP grade groups 1–5. It's one of the three numbers — with PSA and stage — that drive every treatment decision.
If there's concern about spread, a PSMA PET-CT or bone scan maps whether the cancer is confined to the prostate, locally advanced, or metastatic — the picture that determines the treatment plan.
The biopsy grades how aggressive the cells look under the microscope — from 6 to 10, grouped 1–5. It drives treatment as much as stage does.
Gleason 6 · Grade Group 1
Slow-growing cells that may never cause harm in a man's lifetime. Often managed with active surveillance rather than treatment — avoiding side effects while keeping curative options open.
Gleason 7 · Grade Groups 2–3
Moderately abnormal cells with a middle-course behaviour. Treatment choice is individual — surgery, radiation, or in select cases close surveillance — shaped by PSA, stage, age and preference.
Gleason 8–10 · Grade Groups 4–5
Aggressive cells more likely to grow and spread. Usually treated promptly with surgery, radiation plus hormone therapy, or a combination — with good outcomes when caught before spread.
Choice depends on stage, grade, your age, health and preferences — and the right answer for a slow cancer may be 'watch it closely'.
For low-risk, slow-growing cancer: regular PSA tests, repeat MRIs and occasional biopsies, with treatment offered only if the cancer changes. Avoids side effects for years — evidence-based, not 'doing nothing'.
Removal of the prostate, often robotically or laparoscopically. A one-time curative option for localised cancer, with hospital stays measured in days and recovery measured in weeks.
High-energy beams targeted at the prostate over several weeks — no incision, highly effective for localised and locally advanced disease, often combined with hormone therapy.
Radioactive seeds placed inside the prostate, delivering radiation from within. A day-case or overnight option for suitable localised cancers.
Lowers the testosterone that fuels the cancer — used for higher-risk and advanced disease, often alongside radiation, and increasingly as intermittent courses to limit side effects.
For cancer that no longer responds to hormone treatment: chemotherapy plus modern targeted agents and immunotherapies that extend and improve life even in advanced disease.
Surveillance is a valid choice. Many low-grade prostate cancers grow so slowly that treatment's side effects outweigh its benefit. Active surveillance keeps curative options open while avoiding them — and roughly half of men on it avoid treatment for a decade or more.
Most men recover well — and side effects have real, proven fixes. The men who do best are the ones who ask for help early.
Surgery and radiation can affect urinary control. Most men recover well over months, and pelvic-floor physiotherapy — available across SA — speeds that recovery significantly.
Erectile nerves can be affected by treatment. Recovery is often gradual; rehabilitation options, medication and counselling all have a role, and asking early matters.
ADT can bring fatigue, hot flushes, weight change and bone thinning — actively managed with exercise, diet, medication and bone monitoring.
Regular PSA tests check for recurrence. CANSA and the Prostate Cancer Foundation of South Africa run support groups, counselling and practical help through every stage of the journey.
Prostate cancer care exists in both sectors. Public tertiary hospitals provide urology, oncology and radiation services, though non-urgent waits can be long. Private urologists, oncologists and radiotherapy centres offer faster access, and most medical aids cover consultations, biopsies, imaging, surgery, radiation and hormone therapy — with some newer treatments needing pre-authorisation. A GP can start the assessment and PSA test, then refer you on. Early, planned care is almost always simpler, more effective and less costly than treating advanced disease.
Start with a GP — assessment and PSA referral
Public hospitals: full treatment, longer waits
Private sector: faster, most medical aids cover it
CANSA & Prostate Cancer Foundation: support and screening drives
A GP can test and refer; urologists investigate and treat; oncologists handle radiation and advanced disease. Find HPCSA-registered professionals across South Africa — and book the test before symptoms ever appear.
There’s a statistic buried in South Africa’s cancer data that should organise how every man over 40 thinks about his health: prostate cancer is our most frequently diagnosed male cancer, and it is disproportionately lethal here — not because the disease is different, but because we find it late. In many high-income countries, most prostate cancers are found through routine screening while still confined to the gland. In South Africa, a large share of men first learns of the disease when it has already spread to bone. Same cancer, radically different outcomes — separated by a blood test that costs less than a tank of fuel.
The higher stakes fall unevenly. Black South African men carry among the highest incidence rates recorded anywhere in the world, present at younger ages, and are more often diagnosed at advanced stages — driven by lower screening uptake, distance from care, cost, and the cultural silence around men’s health that turns a routine exam into a taboo. Family history compounds it: a father or brother with the disease roughly doubles risk, and BRCA mutations — usually discussed only in women’s health — raise it further. None of this is a reason for fear. All of it is a reason to move the screening age up and the appointment date forward.
What makes late diagnosis so wasteful is how treatable early disease is. Confined prostate cancer has five-year survival above 90%, and modern care is genuinely sophisticated: MRI-guided biopsies that avoid unnecessary procedures, Gleason grading that separates cancers needing treatment from those needing watching, active surveillance that lets half of low-risk men avoid treatment for a decade or more, robotic surgery, precisely-targeted radiation, and — for advanced disease — a new generation of hormone, targeted and immunotherapies that extend life by years. Even metastatic prostate cancer in 2026 is a managed chronic disease in ways it simply wasn’t a generation ago.
The practical pathway for a South African man is short. Know your start age — 50, or 40–45 with Black African ancestry or a family history. Get a PSA test and a prostate exam, and if the result warrants it, follow the sequence: repeat test, MRI, biopsy if indicated — nobody is rushed into anything on one number. If diagnosed, engage properly with the grading and staging conversation before choosing treatment; the right choice for a Gleason 6 cancer in a 70-year-old is very different from a Gleason 9 in a 55-year-old. Use the support that exists — CANSA and the Prostate Cancer Foundation run screening drives and support groups across the country, and both sectors treat this disease daily.
And if there’s one sentence to carry away: prostate cancer is the cancer where showing up early changes everything. It rarely announces itself, it grows quietly for years, and it rewards the man who goes looking before it makes him look. Book the test, know your number, and encourage your father, brothers and friends to do the same — in this disease, the lives screening saves are usually the ones we love.